GlassScriptPhysician profile
James C Stevens
NPI 1437156239
$5,072.58
in general payments reported to CMS, 2019-2025
28 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $73.38 · 2021: $700 · 2022: $847 · 2023: $1,652 · 2024: $690 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,629 · Honoraria: $950 · Food and Beverage: $700 · Education: $16.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,628.75 |
| Honoraria | $950.00 |
| Food and Beverage | $700.46 |
| Education | $16.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $2,578.75 | 2023-2025 | Lumryz |
| Abbvie INC. | $1,227.73 | 2021-2023 | Botox, Ubrelvy, Qulipta |
| Biohaven Pharmaceutical Holding Company LTD. | $189.58 | 2022 | |
| Argenx US, INC. | $171.17 | 2022-2023 | Vyvgart |
| Novartis Pharmaceuticals Corporation | $148.17 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $125.23 | 2021 | |
| Allergan, INC. | $102.67 | 2019-2020 | |
| Biogen, INC. | $82.58 | 2019-2023 | Spinraza |
| Pfizer INC. | $60.12 | 2023 | |
| Amgen INC. | $49.29 | 2022 | |
| Alkermes, INC. | $41.68 | 2019-2023 | Vivitrol |
| Emd Serono, INC. | $40.61 | 2022-2023 | Mavenclad |
| Jazz Pharmaceuticals INC. | $38.28 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $34.85 | 2023 | Nuplazid |
| Genzyme Corporation | $33.35 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $26.28 | 2023 | Nourianz |
| Celgene Corporation | $22.92 | 2023 | Zeposia |
| Supernus Pharmaceuticals, INC. | $21.40 | 2020 | |
| Ge Healthcare | $17.01 | 2019 | |
| Axsome Therapeutics, INC. | $16.69 | 2023 | Sunosi |
| Acorda Therapeutics, INC | $16.24 | 2020 | |
| Ucb, INC. | $14.94 | 2024 | Rystiggo |
| Sunovion Pharmaceuticals INC. | $13.04 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.